Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
ApexOnco Front Page
Recent articles
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
Though lung cancer looks promising a partner is now needed.
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
The company’s AN9025 will shortly enter phase 1.
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
But the group still hopes to get IGV-001 approved based on overall survival data.
